Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Totally implantable system for peritoneal access.

C E Pfeifle, S B Howell, M Markman

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |November 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Differences in Discounting Behavior and Brain Responses for Food and Money Reward.

    eNeuro·2024
    Same author

    Apical hypertrophic cardiomyopathy: A case series at a Brazilian referral center with a maximal follow-up of 15 years.

    Annales de cardiologie et d'angeiologie·2021
    Same author

    Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer.

    European journal of gynaecological oncology·2018
    Same author

    Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach.

    Current oncology (Toronto, Ont.)·2018
    Same author

    Surgical intervention in relapsed ovarian cancer is beneficial: contra.

    Annals of oncology : official journal of the European Society for Medical Oncology·2013
    Same author

    The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy.

    Annals of oncology : official journal of the European Society for Medical Oncology·2011
    Same journal

    Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    Same journal

    Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    Same journal

    Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    Same journal

    Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    Same journal

    Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    Same journal

    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    See all related articles

    The Port-A-Cath system offers excellent patient acceptance for intraperitoneal chemotherapy delivery. While fibrin deposition can impede flow, mechanical failures were absent, making it a reliable option for peritoneal access.

    Area of Science:

    • Oncology
    • Medical Devices
    • Surgical Procedures

    Background:

    • Intraperitoneal chemotherapy requires reliable and safe access to the peritoneal cavity.
    • Totally implantable devices offer a discreet and long-term solution for repeated access.
    • The Port-A-Cath system is one such device evaluated for this purpose.

    Purpose of the Study:

    • To evaluate the safety and efficacy of the Port-A-Cath system for peritoneal access in cancer patients receiving intraperitoneal chemotherapy.
    • To assess the device's performance over a significant patient-years period.
    • To identify potential complications and failure modes associated with the Port-A-Cath.

    Main Methods:

    • Fifty-six Port-A-Cath systems were implanted in 54 cancer patients undergoing intraperitoneal chemotherapy.

    Related Experiment Videos

  • The study involved 32 patient years of follow-up.
  • Data collected included device usage, complications, and patient acceptance.

    • Main Results:

    • A total of 401 entries were made for various procedures including chemotherapy, paracentesis, and lavage.
    • No mechanical failures of the Port-A-Cath devices were reported.
    • Six episodes of peritonitis occurred, primarily due to Staphylococcus species. Fibrin deposition was the main cause of catheter failure, impacting flow.

    Conclusions:

    • The Port-A-Cath system demonstrates excellent patient acceptance and reliability for intraperitoneal chemotherapy delivery.
    • Fibrin deposition is the primary limitation, necessitating monitoring for flow obstruction.
    • The system represents a viable option for long-term peritoneal access with a low rate of serious complications.